CorMedix (NASDAQ: CRMD) reported Q3 EPS of $1.26, $0.83 better than the analyst estimate of $0.43. Revenue for the quarter came in at $104.28 million versus the consensus estimate of $65.92 million.

For earnings history and earnings-related data on CorMedix (CRMD) click here.